bioRxiv · 10.1101/669812
BTLA and PD-1 employ distinct phosphatases to differentially repress T cell signaling
Abstract
T cell-mediated destruction of tumors and virus-infected cells is restricted by co-inhibitory receptors such as programmed cell death protein 1 (PD-1). Monoclonal antibodies blocking PD-1 have produced impressive clinical activity against human cancers, but durable response is limited to a minority of patients. Previous results suggest that B and T lymphocyte attenuator (BTLA), a co-inhibitory receptor structurally related to PD-1, may contribute to the resistance to PD-1 targeted therapy and co-blockade of BTLA can enhance the efficacy of anti-PD-1 immunotherapy. However, the biochemical mechanism by which BTLA represses T cell activity and to what extent the mechanism differs from that of PD-1 is unknown. Here we examine differences in the ability of BTLA and PD-1 to recruit effector molecules and regulate T cell signaling. We show that PD-1 and BTLA recruit different tyrosine phosphatases to regulate either CD28 or T cell antigen receptor (TCR)-signaling cascades. Our data reveal unexpected disparities between two structurally related immune checkpoints and two phosphatase paralogs.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Xu, X., Fulzele, A., Zhao, Y., Wu, Z., Hu, Y., Jiang, Y., Ma, Y., Wang, H., Fu, G., Bennett, E., HUI, E.. 2019-06-14. BTLA and PD-1 employ distinct phosphatases to differentially repress T cell signaling. https://doi.org/10.1101/669812
Cite the original work for its findings. Save a collection to share your selection of sources.